MedTrace Logo

Obstructive Sleep Apnea (OSA) in Pulmonary Arterial Hypertension (PAH)

NCT01835080 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 2

Last updated 2020-06-16

No results posted yet for this study

Summary

The purpose of this study is to determine whether pulmonary arterial hypertension can worsen or even cause sleep apnea. It is hypothesized that if pulmonary arterial hypertension does indeed worsen or cause sleep apnea, then the treatment should first focus on the underlying pulmonary arterial hypertension instead of the sleep apnea.

To determine if a person has sleep apnea, they will undergo one overnight polysomnogram (sleep study). If it is found that they have mild to moderate sleep apnea, then the subject will be invited to continue in the study and their pulmonary arterial hypertension will be treated by their managing primary physician. After the subject has had treatment for their pulmonary arterial hypertension, the study center will have them return for a follow up sleep study to learn the effects of pulmonary arterial hypertension treatment management on their sleep apnea, 12-24 weeks after the first sleep study.

Conditions

Sponsors & Collaborators

  • Brown University

    collaborator OTHER

  • Tufts University

    collaborator OTHER

  • George Washington University

    collaborator OTHER

  • Inova Health Care Services

    lead OTHER

Principal Investigators

  • Nargues Weir, MD · NIH/Inova Fairfax Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2014-03-31
Completion
2014-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01835080 on ClinicalTrials.gov